Glucose-Responsive Insulin Analogues with Conformational Switch
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin analogues fail to effectively mitigate the risk of hypoglycemia while maintaining glycemic control, particularly due to suboptimal glucose-responsive properties and potential for increased mitogenicity.
Innovation Solution
Development of insulin analogues with a glucose-dependent conformational switch, featuring a phenylboronic acid derivative at the N-terminus of the A chain and saccharide modifications at the C-terminus of the B chain, which modulates insulin receptor binding and hexamer disassembly in response to glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin analogues are designed to bind to insulin receptors irrespective of glucose concentration, then glycemic control is achieved, but the risk of hypoglycemia increases
Solution Approach 1:
The patent applies dynamics by making the insulin analogue's binding affinity dynamic rather than static. The conformational switch mechanism allows the insulin analogue to transition between high-affinity and low-affinity states in response to glucose concentration changes, enabling the system to adapt its activity level to physiological conditions and avoid harmful hypoglycemic effects while maintaining reliable glycemic control.
Solution Approach 2:
The patent utilizes parameter changes by modifying the binding affinity parameter of the insulin analogue based on glucose concentration. The conformational switch responds to glucose level changes by altering the conformational state of the insulin analogue, which directly changes its binding affinity parameter for the insulin receptor, thereby adjusting its biological activity to match physiological needs.
2Reliability
If insulin analogues are designed with enhanced receptor affinity, then metabolic regulation is improved, but mitogenic effects are augmented
Solution Approach 1:
The patent applies dynamics by making the insulin analogue's receptor interaction dynamic rather than constant. The conformational switch mechanism ensures that high receptor affinity is only achieved when glucose concentrations are elevated, creating a conditional relationship between metabolic regulation efficacy and mitogenic risk that adapts to physiological state.
Solution Approach 2:
The patent utilizes parameter changes by linking the binding affinity parameter to glucose concentration levels. The conformational switch mechanism causes the binding affinity parameter to increase only when glucose levels are high, thereby enhancing metabolic regulation precisely when needed while minimizing mitogenic effects during normal or low glucose states.
3Ease of operation
If conventional insulin formulations are used, then ease of administration is maintained, but glucose-responsive properties are suboptimal
Solution Approach 1:
The patent applies self-service by enabling the insulin analogue to automatically sense and respond to glucose concentration changes through its conformational switch mechanism. The molecule self-regulates its binding affinity based on physiological glucose levels without requiring external control systems, complex delivery devices, or patient monitoring, thereby maintaining ease of administration while achieving superior glucose-responsive properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These insulin analogues exhibit enhanced glucose-responsive binding to the insulin receptor and controlled hexamer disassembly, reducing the risk of hypoglycemia and maintaining effective glycemic control, while also minimizing mitogenic effects.
Implementation Method 1
a glucose-dependent conformational switch, featuring a phenylboronic acid derivative at the N-terminus of the A chain and saccharide modifications at the C-terminus of the B chain
Data Source
Figure 1A
Figure 1B~1C
Figure 2
AI summary
A two-chain insulin analogue contains an A chain modified by (i) a monomeric glucose-binding element at or near its N terminus and (ii) a B chain modified by at or near its C terminus by an element that reversibly binds to the monomeric glucose-binding element such that this linkage is displaceable by glucose. The monomeric glucose-binding element may be phenylboronic acid derivative (optionally halogenated). The B chain may be modified by a diol-containing element derived from a monosaccharide, disaccharide or oligosaccharide, a non-saccharide diol-containing moiety or a α-hydroxycarboxylate-containing moiety. The analogue can be manufactured by trypsin-mediated semi-synthesis. Formulations can be at strengths U-10 to U-1000 in soluble solutions at pH 7.0-8.0 with or without zinc ions at a molar ratio of 0.0-3.0 ions per insulin analogue monomer. A patient with diabetes mellitus may be treated with subcutaneous, intraperitoneal, or oral administration of a physiologically effective amount of the insulin analogue.